Navigation Links
Endo Pharmaceuticals Raises 2011 Financial Guidance and Reports Strong Fourth Quarter 2010 Financial Results
Date:2/28/2011

operations:(1)

To exclude amortization of commercial intangible assets related to marketed products of $83,974 and the impact of inventory step-up recorded as part of acquisition accounting of $6,289.(2)

To exclude certain start-up costs and separation benefits incurred in connection with continued efforts to enhance the company's operations.(3)

To exclude a milestone-like payment and milestone and upfront payments to partners of $23,850 and certain costs incurred in connection with continued efforts to enhance the cost structure of the company of $512.(4)

To exclude the impairment of Octreotide and Pagoclone of $22,000 and $13,000, respectively.(5)

To exclude acquisition-related costs of $70,396 as well as the impact, under purchase accounting, of a gain recorded to reflect the change in the company's current estimate of fair value, in accordance with GAAP, of the contingent consideration associated with the Indevus acquisition of $(51,420).(6)

To exclude additional interest expense as a result of adopting ASC 470-20 of $17,296 and to exclude amortization of the premium on debt acquired from Indevus of ($313).(7)

To exclude changes in fair value of financial instruments, net.(8)

To reflect the cash tax savings results from our recent acquisitions and the tax effect of the pre-tax adjustments above at applicable tax rates.Twelve Months Ended December 31, 2009 (unaudited) Actual Reported (GAAP) AdjustmentsAdjustedTotal Revenues$  1,460,841

$
8212;$  1,460,841Costs and expenses: Cost of revenues

375,058

(74,199)

(1)

300,859 Selling, general and administrative

534,523

(2,549)

(2)

531,974 Research and development

185,317

(77,099)

(3)

108,218Impairment of intangibles

69,000

(69,000)

(4)

—Acquisition-related items

(93,081)

93,081

(5)

̵
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology
2. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
3. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
4. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
6. UCLA and Sound Pharmaceuticals Identify a Key Hearing Regeneration Protein in the Human Inner Ear
7. JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
9. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
10. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
11. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and TORONTO , Aug. ... (OTCQB: GNBT) today announced the issuance of a white ... proprietary buccal insulin spray product.  The white paper was ... the Company,s stockholders by Dr. James H. Anderson, ... white paper may be viewed online on the Generex ...
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... , August 27, 2015 ... Persistence Market Research titled "Global Market Study on ... Growth by 2021", the urinary catheters market is expected to ... of 2015. It is anticipated to expand at ... reach US$1,755.0 Mn by 2021. View ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... and Chief Executive Officer, will present at the Cowen ... Boston Marriott Copley Place.  The presentation is scheduled for ...
... 2011 HeartWare International, Inc. (Nasdaq: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to make an investor presentation at ... a.m. Eastern Time on Tuesday, March 15, 2011. The ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference 2
(Date:8/27/2015)... ... 27, 2015 , ... StayWell, a leading provider of patient ... ICD-10 ready and available to all clients. All Krames Patient Education content has ... more targeted and return a more comprehensive data set of content than the ...
(Date:8/27/2015)... , ... August 27, 2015 , ... In addition to ... University now offers a third doctoral program at its main campus in Reading: Doctor ... terminal degree program designed to prepare advanced practice nurses for the highest level of ...
(Date:8/27/2015)... ... August 27, 2015 , ... Market ... market research promotion on the Internet. MarketPublishers.com is now authorised to distribute ... the partnership agreement, Natalie Aster, Assistant Manager at Partners Department, noted: "Black ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Sunbelt® Bakery, ... high fructose corn syrup, is changing the expectation of how protein bars should taste ... indulgent taste unlike any other protein bar on the market today. , The ...
(Date:8/27/2015)... La Mirada, Ca (PRWEB) , ... August 27, ... ... throughout Southern California including Los Angeles, Riverside, San Bernardino, and Orange ... executive employees, Healthpointe’s executive physical exams are offered annually at all of its ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Healthpointe Now Offering Executive Physicals 2
... Using small molecules (purine analogs) scientists ... lung cancer, a common obstacle to successful, ... - HTDS www.htdsmedical.com (HTDS) - The issuer,s ... brings attention to its Mindup Bioresearch cancer project working ...
... At a Los Angeles gala, family and friends ... in paying tribute to women,s health advocate and fitness ... Beverly Wilshire Hotel where friends toasted LaLanne for being ... in shape and lead healthier lifestyles. , (Photo: ...
... French . , Winnipeg (October 14, 2009) The ... (CIHR) today announced support for five new research projects ... virus. "Canada is a global leader in ... on a safe and effective H1N1 vaccine," said Health Minister ...
... tumor growth without harmful therapies, study suggests , WEDNESDAY, ... scientists closer to their goal of treating pancreatic cancer ... The researchers, who were scheduled to report their findings ... 11-15 in Chicago, have created a bioengineered "construct" that ...
... GLENDALE, Calif., Oct. 14 Although some parents may ... www.LakesideCommunityHealthcare.com , one of Southern California,s ... about both the safety of and access to the ... www.LakesideFluInfo.com to give patients direct access ...
... Oct. 14 Cardium Therapeutics (NYSE Amex: CXM ... 2b clinical trial of Excellarate(TM) for the potential treatment ... on the Company,s Gene Activated Matrix (GAM) technology platform. ... product candidate (GAM501, which is a combination of Ad5PDGF-B ...
Cached Medicine News:Health News:Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression 2Health News:Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression 3Health News:Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression 4Health News:Jack LaLanne Celebrated as Fitness Icon at Star-Studded Birthday Bash 2Health News:Government of Canada supports scientific research to deepen knowledge of H1N1 flu virus 2Health News:Stem Cells Being Tested to Fight Pancreatic Cancer 2Health News:Leading Southern California Physicians Report Patient Fears About Complexities of Flu Season 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 3Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 4Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 5Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 6Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 7Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 8Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 9Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 10Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 11Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 12Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 13Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 14
Cold light source single outlet....
Cold light source single outlet....
Cold light source single outlet....
Cold light source triple outlet....
Medicine Products: